Osbpl11 Antibody

What is OSBPL11 and what are its key molecular characteristics?

OSBPL11, also known as ORP11, is a member of the oxysterol-binding protein family involved in lipid metabolism and transport. The protein has a molecular weight of approximately 84 kDa and consists of 747 amino acids . It is encoded by the OSBPL11 gene (Gene ID: 114885) with UniProt ID Q9BXB4 . Research indicates that OSBPL11 forms a functional dimer with ORP9 that promotes sphingomyelin synthesis, suggesting an important role in cellular lipid homeostasis . Understanding OSBPL11's structure and function is essential for research into lipid-related cellular processes and potential disease associations.

What applications are OSBPL11 antibodies validated for?

Based on current research tools, OSBPL11 antibodies have been validated for multiple applications:

Each application requires specific optimization of antibody concentration, incubation conditions, and detection methods to achieve optimal results. For IHC applications, antigen retrieval is typically recommended with TE buffer pH 9.0 or citrate buffer pH 6.0 .

What is the difference between monoclonal and polyclonal OSBPL11 antibodies?

The choice between monoclonal and polyclonal OSBPL11 antibodies significantly impacts experimental outcomes:

Monoclonal antibodies offer superior reproducibility but may fail if their single epitope is masked or modified. Polyclonal antibodies provide better sensitivity through recognition of multiple epitopes but may introduce more cross-reactivity issues. Advanced researchers should consider maintaining both types in their experimental toolkit, selecting based on the specific application requirements.

How do I select the appropriate OSBPL11 antibody based on species reactivity?

Selecting an OSBPL11 antibody with appropriate species reactivity is crucial for experimental success. Current commercial antibodies offer varied cross-reactivity profiles:

When working with mouse samples using mouse-derived antibodies (e.g., NBP2-73160MFV450), researchers should consider using Mouse-On-Mouse blocking reagents to reduce background signal in IHC and ICC experiments . For comparative studies across species, select antibodies validated in all target species to ensure consistent epitope recognition and avoid introducing methodological artifacts.

What is the optimal sample preparation protocol for detecting OSBPL11 in Western blots?

For optimal OSBPL11 detection in Western blots, follow this methodological approach:

• Lysate preparation: Extract protein from validated positive control cells (HeLa or HepG2 ) using RIPA buffer supplemented with protease inhibitors. For tissue samples, homogenize in cold lysis buffer (1:10 w/v).

• Protein quantification: Use BCA or Bradford assay to ensure equal loading (20-50 μg per lane recommended).

• Sample preparation: Mix with 4X Laemmli buffer containing β-mercaptoethanol (5% final). Heat at 95°C for 5 minutes.

• Gel electrophoresis: Use 8-10% SDS-PAGE gels (appropriate for 84 kDa proteins ).

• Transfer conditions: Transfer to PVDF membrane at 100V for 60-90 minutes in cold transfer buffer containing 20% methanol.

• Blocking: Block with 5% non-fat milk in TBST for 1 hour at room temperature.

• Antibody incubation: Incubate with primary OSBPL11 antibody diluted in blocking buffer (1:500-1:3000 for 11318-1-AP ). Incubate overnight at 4°C with gentle agitation.

• Detection: After appropriate washing and secondary antibody incubation, visualize using chemiluminescence. The expected molecular weight is 84 kDa .

Always include positive control samples and verify band specificity using appropriate controls (e.g., OSBPL11 knockdown lysates).

How can I optimize co-immunoprecipitation experiments to study OSBPL11 protein interactions?

Co-immunoprecipitation (co-IP) is valuable for investigating OSBPL11 interactions, particularly the ORP9-ORP11 dimer mentioned in the literature . For optimal results, implement this methodological approach:

• Buffer optimization: Use a mild, non-denaturing lysis buffer (e.g., 25 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 1 mM EDTA, 5% glycerol) supplemented with protease and phosphatase inhibitors to preserve protein-protein interactions.

• Antibody selection: Choose antibodies validated for IP applications. For OSBPL11, the rabbit polyclonal antibody 11318-1-AP has been validated in mouse testis tissue , using 0.5-4.0 μg antibody per 1.0-3.0 mg of total protein lysate.

• Pre-clearing: Pre-clear lysates with appropriate control IgG and Protein A/G beads for 1 hour at 4°C to reduce non-specific binding.

• Cross-linking consideration: For transient interactions, consider using membrane-permeable crosslinkers (DSP, 1 mM) before cell lysis.

• Reciprocal IP: Confirm interactions by performing parallel IPs with antibodies against both OSBPL11 and its interaction partner (e.g., ORP9).

• Controls: Always include negative controls (non-specific IgG) and input samples (5-10% of lysate used for IP).

• Elution and detection: Elute complexes by boiling in 2X Laemmli buffer and analyze by Western blotting with antibodies against both OSBPL11 and potential interaction partners.

When investigating the ORP9-OSBPL11 dimer specifically, ensure antibody epitopes do not interfere with the dimerization interface to prevent false negative results.

What strategies can resolve cross-reactivity issues with OSBPL11 antibodies?

Cross-reactivity is a common challenge with OSBPL11 antibodies, particularly given the sequence similarity within the OSBP protein family. Implement these methodological approaches to address this issue:

• Epitope analysis: Review the immunogen sequence information provided by manufacturers. For example, ABIN185121 targets the C-terminal peptide sequence KPLWKIIPTTQPAE . Compare this sequence against other OSBP family members using protein BLAST to identify potential cross-reactivity.

• Validation controls:

  • Positive controls: Use cells with known OSBPL11 expression (HeLa, HepG2 )

  • Negative controls: Implement OSBPL11 knockdown/knockout models

  • Peptide competition: Pre-incubate antibody with immunizing peptide to confirm specificity

• Antibody titration: Test a concentration gradient (e.g., 1:500, 1:1000, 1:3000 for WB applications ) to identify the optimal signal-to-noise ratio.

• Blocking optimization: For high background, increase blocking reagent concentration (5-10% BSA/milk) or try alternative blockers (casein, fish gelatin).

• Mouse-on-mouse considerations: When using mouse-derived antibodies (like NBP2-73160MFV450 ) on mouse tissues, implement specialized blocking reagents to reduce endogenous Ig detection.

• Multiple antibody validation: Compare results from multiple antibodies targeting different OSBPL11 epitopes to differentiate true signal from cross-reactivity.

• Sample preparation adjustment: Modify fixation protocols for IHC/ICC or lysis conditions for WB/IP to improve epitope accessibility while reducing non-specific binding.

How should I approach OSBPL11 antibody validation in knockout or knockdown models?

Rigorous validation of OSBPL11 antibodies using genetic models is essential for ensuring experimental reproducibility and accuracy. Implement this comprehensive validation workflow:

• Generate appropriate models:

  • CRISPR/Cas9 knockout cell lines

  • siRNA knockdown (transient, 48-72h)

  • shRNA stable knockdown cell lines

• Validation methodology:

  • Western blotting: Compare OSBPL11 band intensity (at 84 kDa ) between control and KO/KD samples

  • Immunofluorescence: Assess reduction in cellular staining

  • Flow cytometry: Quantify signal reduction in knockout populations

• Quantitative assessment:

  • Densitometry analysis of Western blot bands

  • Statistical analysis of signal reduction relative to control

  • Correlation with mRNA knockdown efficiency (qRT-PCR)

• Cross-antibody validation: Test multiple OSBPL11 antibodies targeting different epitopes to confirm consistent results across reagents.

• Rescue experiments: Re-express OSBPL11 in knockout cells to confirm signal recovery, providing definitive evidence of antibody specificity.

• Documentation: Generate comprehensive validation data including images of Western blots showing complete/partial signal reduction in knockout/knockdown models compared to controls.

This validation approach not only confirms antibody specificity but also establishes appropriate positive and negative controls for future experiments.

What are the key considerations when studying the ORP9-OSBPL11 dimer formation?

The ORP9-OSBPL11 dimer has been implicated in sphingomyelin synthesis , making it an important research target. Consider these methodological approaches when investigating this complex:

• Antibody selection strategy:

  • Epitope consideration: Choose antibodies targeting regions outside the dimerization interface

  • For co-localization studies: Select antibodies from different host species (e.g., rabbit anti-OSBPL11, mouse anti-ORP9)

  • For functional studies: Test whether antibodies interfere with dimer formation or function

• Complementary approaches to co-IP:

  • Proximity ligation assay (PLA): Visualize protein interactions in situ with <40nm proximity

  • FRET/BRET analysis: Quantify direct protein interactions in living cells

  • Size exclusion chromatography: Separate and identify protein complexes

• Dimerization interface studies:

  • Deletion mutants: Generate truncated proteins to map interaction domains

  • Site-directed mutagenesis: Identify critical residues for dimerization

  • Crosslinking mass spectrometry: Determine precise interaction sites

• Functional analysis:

  • Sphingomyelin synthesis assays: Measure functional consequences of dimer disruption

  • Lipid binding assays: Determine how dimerization affects lipid binding properties

  • Subcellular localization: Assess whether dimerization affects protein localization

• Controls and validation:

  • Expression level considerations: Ensure physiological expression to avoid artifacts

  • Cell type specificity: Determine whether dimerization occurs in all cell types or is context-dependent

  • Comparison with other ORP family dimers: Establish common and unique features

This multifaceted approach can provide robust evidence for the existence, molecular details, and functional significance of the ORP9-OSBPL11 dimer.

How do I optimize OSBPL11 antibody performance in flow cytometry and imaging applications?

For flow cytometry and imaging applications with conjugated antibodies like the mFluor Violet 450-labeled OSBPL11 antibody (NBP2-73160MFV450) , implement these optimization strategies:

• Flow cytometry optimization:

  • Titration experiment: Test 2-fold serial dilutions to determine optimal antibody concentration

  • Controls implementation:

    • Unstained control: Establish autofluorescence baseline

    • Isotype control: Mouse IgG conjugated to same fluorophore

    • FMO (Fluorescence Minus One): Define positive population boundaries

    • Positive control: HeLa or HepG2 cells with known OSBPL11 expression

  • Fixation/permeabilization optimization: Test different permeabilization reagents to optimize intracellular detection

  • Compensation: When using multiple fluorophores, establish proper compensation using single-color controls

• Immunofluorescence microscopy optimization:

  • Fixation method comparison: Test paraformaldehyde (4%) vs. methanol fixation

  • Permeabilization options: Compare Triton X-100 (0.1-0.5%), saponin (0.1%), or digitonin (25 μg/ml)

  • Blocking protocol: Use 5-10% normal serum from secondary antibody host species

  • Signal amplification: Consider tyramide signal amplification for low abundance targets

  • Co-staining protocols: For co-localization with ORP9, use compatible antibody pairs from different host species

• General considerations:

  • Signal-to-noise optimization: Balance between sufficient signal detection and minimal background

  • Photobleaching prevention: Use anti-fade mounting media for imaging

  • Z-stack acquisition: For 3D localization in confocal microscopy

  • Resolution enhancement: Consider super-resolution techniques (STED, PALM, STORM) for detailed localization studies

• Data analysis protocols:

  • For flow cytometry: Establish consistent gating strategies

  • For microscopy: Implement quantitative co-localization analysis (Pearson's coefficient, Manders' coefficient)

This methodological approach ensures optimal detection of OSBPL11 in both flow cytometry and imaging applications while minimizing artifacts and background issues.